{"id":1237,"date":"2017-03-14T10:04:19","date_gmt":"2017-03-14T02:04:19","guid":{"rendered":"http:\/\/web.csh.org.tw\/web\/222010\/?p=1237"},"modified":"2017-05-04T14:35:36","modified_gmt":"2017-05-04T06:35:36","slug":"%e4%b9%be%e7%99%ac%e5%8f%8a%e4%b9%be%e7%99%ac%e6%80%a7%e9%97%9c%e7%af%80%e7%82%8e%e4%b9%8b%e5%85%8d%e7%96%ab%e6%a8%99%e9%9d%b6%e8%97%a5%e7%89%a9","status":"publish","type":"post","link":"https:\/\/web.csh.org.tw\/web\/222010\/?p=1237","title":{"rendered":"\u3010\u904e\u654f\u514d\u75ab\u98a8\u6fd5\u79d1\u3011\u4e7e\u766c\u53ca\u4e7e\u766c\u6027\u95dc\u7bc0\u708e\u4e4b\u514d\u75ab\u6a19\u9776\u85e5\u7269"},"content":{"rendered":"

\u6587\/\u904e\u654f\u514d\u75ab\u98a8\u6fd5\u79d1 \u9b4f\u6b63\u5b97\u4e3b\u4efb<\/h4>\n

\u4e7e\u766c\uff0c\u4fd7\u7a31\u725b\u76ae\u766c\uff0c\u662f\u6307\u9811\u56fa\u6027\u7684\u76ae\u819a\u7662\u75b9\u3001\u812b\u5c51\u53ca\u6591\u584a\uff0c\u662f\u4e00\u7a2e\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\uff0c\u7d047-42%\u7684\u4eba\u6703\u5408\u4f75\u95dc\u7bc0\u708e\u3001\u814e\u708e\u53ca\u8679\u5f69\u708e\u7b49\u5408\u4f75\u75c7\uff0c\u4e5f\u6703\u9020\u6210\u808c\u8171\u9644\u8457\u9ede\u767c\u708e\u3002\u6cbb\u7642\u4e7e\u766c\u9700\u540c\u6642\u517c\u9867\u76ae\u819a\u8207\u95dc\u7bc0\uff0c\u5c40\u90e8\u6cbb\u7642\u8207\u514d\u75ab\u8abf\u7bc0\u96d9\u7ba1\u9f4a\u4e0b\uff0c\u624d\u80fd\u771f\u6b63\u6539\u5584\u81ea\u9ad4\u514d\u75ab\u7684\u5931\u8abf\u3002<\/p>\n

\u76ee\u524d\u53f0\u7063\u5df2\u4e0a\u5e02\u4e4b\u514d\u75ab\u6a19\u9776\u85e5\u7269<\/span><\/p>\n

1.\u00a0\u00a0<\/span>\u00a0 \u6297\u816b\u7624\u58de\u6b7b\u56e0\u5b50\u751f\u7269\u88fd\u5291<\/p>\n

I. Etanercept\uff08\u5546\u54c1\u540dEnbrel \u6069\u535a\uff09\u7531\u4e2d\u570b\u5009\u9f20\u5375\u5de2\u7d30\u80de\u7d44\u7e54\u57f9\u990a\u800c\u4f86\u5c0d\u6297\u816b\u7624\u58de\u6b7b\u56e0\u5b50\u7684\u878d\u5408\u86cb\u767d\uff0c\u76ae\u4e0b\u6ce8\u5c04\uff0c\u6bcf\u5468\u5169\u6b21\u3002<\/p>\n

II. Adalimumab\uff08\u5546\u54c1\u540dHumira \u5fa9\u9081\uff09\u4e00\u7a2e\u5168\u4eba\u7684\u816b\u7624\u58de\u6b7b\u56e0\u5b50\u7684\u55ae\u682a\u6297\u9ad4\uff0c\u76ae\u4e0b\u6ce8\u5c04\uff0c\u6bcf\u5169\u5468\u4e00\u6b21\u3002<\/p>\n

III. Golimumab\uff08\u5546\u54c1\u540dSimponi \u6b23\u666e\u5c3c\uff09\u4e00\u7a2e\u5168\u4eba\u7684\u816b\u7624\u58de\u6b7b\u56e0\u5b50\u7684\u55ae\u682a\u6297\u9ad4\uff0c\u76ae\u4e0b\u6ce8\u5c04\uff0c\u6bcf\u56db\u5468\u4e00\u6b21\uff0c\u4f7f\u7528\u8f03\u65b9\u4fbf\u3002<\/p>\n

2. \u6297IL12\/23\u751f\u7269\u88fd\u5291(anti-p40): Ustekinumab (\u5546\u54c1\u540dStelara \u559c\u9054\u8afe) \u662f\u4e00\u7a2e\u5c0d\u6297IL-12\u53caIL-23\u7d30\u80de\u6fc0\u7d20\u7684\u4eba\u9ad4\u55ae\u682a\u6297\u9ad4\u88fd\u5291\uff0c\u5c6c\u65bc\u9577\u6548\u578b\uff0c\u65bd\u6253\u6642\u9593\u70ba\u7b2c0\u5468\u53ca\u7b2c4\u5468\uff0c\u4e4b\u5f8c12\u5468\u65bd\u6253\u4e00\u6b21\uff0c\u4f7f\u7528\u4e0a\u8f03\u65b9\u4fbf\uff0c\u53ef\u6e1b\u7de9\u4e7e\u766c\u75c7\u72c0\u7d046-7\u6210\u3002<\/p>\n

3. \u00a0Apremilast\uff08\u5546\u54c1\u540dOtezla\uff09\u6291\u5236\u78f7\u9178\u4e8c\u916f\u91764 (PDE4)\u7684\u5c0f\u5206\u5b50\u53e3\u670d\u88fd\u5291\uff0c\u4f5c\u7528\u65bc\u55ae\u78f7\u9178\u74b0\u817a\u82f7\u9178(cAMP)\u3002\u7f8e\u570b\u5df2\u4e0a\u5e02\uff0c\u7528\u65bc\u6cbb\u7642\u6d3b\u52d5\u6027\u4e7e\u766c\u6027\u95dc\u7bc0\u708e\u6210\u4eba\u60a3\u8005\u548c\u9069\u7528\u5149\u7642\u6216\u5168\u8eab\u7642\u6cd5\u7684\u4e2d\u91cd\u5ea6\u6591\u584a\u72c0\u4e7e\u766c\u60a3\u8005\u3002\u6b64\u85e5\u512a\u9ede\u70ba\u526f\u4f5c\u7528\u5c11\uff0c\u7642\u6548\u4e5f\u4f73\uff0cACR20\u7de9\u89e3\u7387\u70ba65.3%\uff0cACR50\u548c70\u7de9\u89e3\u7387\u5206\u5225\u70ba34.0%\u548c19.6%\u3002<\/p>\n

4.\u00a0\u6297IL17\u751f\u7269\u88fd\u5291\uff1aSecukinumab\uff08\u5546\u54c1\u540dCosentyx\uff09\u5df2\u4e0a\u5e02\uff0c\u6bcf\u6708\u76ae\u4e0b\u6ce8\u5c04\u4e00\u91dd\uff0c\u5c0d\u76ae\u819a\u4e7e\u766c\u53ef\u9054\u5230PASI75\u6709\u6548\u738764%\uff0c\u76f8\u8f03\u65bc\u5b89\u6170\u52918%\uff0c\u53ef\u8aaa\u662f\u76ee\u524d\u6cbb\u7642\u4e7e\u766c\u7642\u6548\u6700\u597d\u7684\u85e5\u7269\u4e4b\u4e00\u3002<\/p>\n

\u570b\u5916\u5df2\u4e0a\u5e02\u6216\u81e8\u5e8a\u8a66\u9a57\u4e2d\u7684\u65b0\u85e5<\/span><\/p>\n

1.\u00a0<\/span>Tofacitinib\uff08\u5546\u54c1\u540d Xeljanz\u6377\u6291\u708e\uff09: \u7531\u8f1d\u745e(Pfizer)\u85e5\u5ee0\u7814\u767c\u7684\u300e\u5c0f\u5206\u5b50\u53e3\u670d\u6a19\u9776\u85e5\u7269\u300f\uff0c\u662f\u6700\u53d7\u4eba\u77da\u76ee\u7684\u65b0\u85e5\uff0c\u6a5f\u8f49\u662f\u6291\u5236\u7d30\u80de\u5167\u8a0a\u606f\u50b3\u905e\u5206\u5b50JAK-3\uff0c\u81e8\u5e8a\u8a66\u9a57\u7d50\u679c\u76f8\u7576\u597d\uff0c\u5df2\u5728\u7f8e\u570b\u53ca\u53f0\u7063\u4e0a\u5e02\uff0c\u7528\u65bc\u50b3\u7d71\u514d\u75ab\u8abf\u7bc0\u5291\u7121\u6548\u4e4b\u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e\uff0c\u4f46\u4e7e\u766c\u53ca\u4e7e\u766c\u6027\u95dc\u7bc0\u708e\u4e4b\u7814\u7a76\u4ecd\u9032\u884c\u4e2d\u3002<\/p>\n

2.\u00a0\u65b0\u578b\u6297IL23\u751f\u7269\u88fd\u5291(anti-p19) : Guselkumab\u6bcf\u5169\u500b\u6708\u76ae\u4e0b\u6ce8\u5c04\u4e00\u91dd\uff0c\u66f4\u5c08\u4e00\u6027\u5730\u5c0d\u6297IL-23\u7d30\u80de\u6fc0\u7d20\u7684\u4eba\u9ad4\u55ae\u682a\u6297\u9ad4\u88fd\u5291\uff0c\u521d\u6b65\u7814\u7a76\u986f\u793a\u6548\u679c\u76f8\u7576\u597d\uff0c\u4e0d\u4e9e\u65bc\u73fe\u6709\u4e4b\u559c\u9054\u8afe(Stelara)\u3002<\/p>\n

\u7d50\u8ad6<\/span><\/p>\n

\u8fd1\u5e74\u4f86\uff0c\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u7684\u751f\u7269\u88fd\u5291\u76f8\u7e7c\u554f\u5e02\uff0c\u9019\u4e9b\u65b0\u85e5\u5982\u5b9a\u5411\u5c0e\u5f48\u822c\u7cbe\u78ba\u63cf\u6e96\u7570\u5e38\u7684\u514d\u75ab\u5206\u5b50\uff0c\u4e0d\u6703\u50b7\u5bb3\u6b63\u5e38\u7d30\u80de\uff0c\u9019\u5c31\u662f\u514d\u75ab\u6a19\u9776\u7642\u6cd5\u3002<\/p>\n

\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

\u6587\/\u904e\u654f\u514d\u75ab\u98a8\u6fd5\u79d1 \u9b4f\u6b63\u5b97\u4e3b\u4efb \u4e7e\u766c\uff0c\u4fd7\u7a31\u725b\u76ae\u766c\uff0c\u662f\u6307\u9811\u56fa\u6027\u7684\u76ae\u819a\u7662\u75b9\u3001\u812b\u5c51\u53ca\u6591\u584a\uff0c\u662f\u4e00\u7a2e\u81ea\u9ad4\u514d\u75ab\u75be… <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,13],"tags":[],"class_list":["post-1237","post","type-post","status-publish","format-standard","hentry","category-hiv-faq","category-doc-heaedu"],"_links":{"self":[{"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=\/wp\/v2\/posts\/1237"}],"collection":[{"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1237"}],"version-history":[{"count":6,"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=\/wp\/v2\/posts\/1237\/revisions"}],"predecessor-version":[{"id":1690,"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=\/wp\/v2\/posts\/1237\/revisions\/1690"}],"wp:attachment":[{"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/web.csh.org.tw\/web\/222010\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}